AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

The deal – which includes an upfront payment of $49 million – will see the two companies collaborate on the discovery of molecular glue degraders "for multiple targets in several disease areas ...

Molecular targets are specific molecules in ... Recent studies have highlighted the evolution and potential of PROTAC technology. PROTACs are designed to bind to a target protein and an E3 ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...